SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DUSA (DUSA) Pharmaceutical
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. John M. de Castro who wrote (45)1/10/1999 1:25:00 PM
From: Ron Harvey  Read Replies (1) of 101
 
While the results were highly encouraging, they're still part of a Phase I/II clinical trial and far away from FDA approval and profitable product. The price fate of Dusa will remain with FDA approval of the AK treatment and a good deal with a partner, preliminarily via anticipation and then from the actualities. Meanwhile, I thought the volume and price action on Friday, after a brief bout of heavy selling, was very encouraging and augurs well for things to come. Once DUSA breaks 8, it should move nicely.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News